Huawei Watch GT 7, Watch D3 and the Still-Unreleased Blood Sugar Device

Huawei’s September 2026 watch launches brought two different approaches to health tracking: the Watch GT 7 Series focuses on fitness and risk assessments, while the Watch D3 measures blood pressure. A blood-sugar testing device discussed by Huawei executive He Gang is a separate, unreleased prospect—not a feature of either new watch. 4328

Watch GT 7 Series: fitness features and health-risk assessments

Huawei launched the Watch GT 7 and GT 7 Pro in China on August 5, 2026, then introduced them internationally at its September 2 event in Munich. The series adds sports features, including skiing modes, alongside assessments intended to flag potential coronary-heart-disease and diabetes-related risks. In supported markets, both GT 7 models offer a high-blood-sugar-risk assessment; neither directly measures glucose. 748

UK orders opened on September 2, starting at £279.99 for the GT 7 and £379.99 for the GT 7 Pro. The series is expected in the Philippines in October. Features and availability vary by market, so a regional launch does not establish that every health feature is available everywhere. 7198

Watch D3: blood pressure, not blood sugar

Introduced internationally on September 2, the Watch D3 uses an inflatable airbag in its strap to take wrist-based blood-pressure readings. It supports 24-hour ambulatory monitoring, including readings during sleep, and adds pre- and post-exercise measurements and reminders. Its blood-pressure function has CE marking under the EU Medical Device Regulation; that status does not apply to Huawei’s proposed glucose device. 1834

The D3 became available in the UK on September 23 for £399.99. A Philippine launch is expected in October. 1819

What Huawei has confirmed about a future glucose device

He Gang, head of Huawei’s consumer business, said the company is working on a blood-sugar testing device following four years of research, according to reports published after his September 25 comments. Huawei has not identified a product or announced a release date. A report’s suggestion that it might arrive next year is not a company launch commitment. 29

Its form factor—including whether it will be a watch—remains undisclosed. So do its glucose-sensing method, measurement accuracy and route to medical-device authorization. Although reporting discusses non-invasive testing and near-infrared spectroscopy, it does not establish spectroscopy as the method Huawei’s device will use. 29

Why a risk alert is not a glucose reading

Huawei says its existing Diabetes Risk Study uses watch data such as heart rate and sleep, gathered over 3–14 days, to assess hyperglycemia risk. Huawei states that the feature is not intended for medical use. It does not provide a blood-glucose value or replace a glucose test. Whether Huawei’s future device can deliver reliable glucose measurements—and on what terms—remains to be shown. 129